INNOVIVA, INC. Amortization of Debt Issuance Costs
INNOVIVA, INC. (INVA) reported Amortization of Debt Issuance Costs of $166.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-10-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2021-10-27
- INNOVIVA, INC. amortization of debt issuance costs for the quarter ending 2021-09-30 was $166.00K, a 9.21% increase year-over-year.
- INNOVIVA, INC. amortization of debt issuance costs for the quarter ending 2020-09-30 was $152.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 9 month |
|---|---|---|
| 2021-09-30 | $166.00K 10-Q · filed 2021-10-27 | $487.00K 10-Q · filed 2021-10-27 |
| 2020-09-30 | $152.00K 10-Q · filed 2021-10-27 | $446.00K 10-Q · filed 2021-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |